The safety of oral use of L-glutamine in middle-aged and elderly individuals
| Autor: | Paulo Roberto Leitão de Vasconcelos, Francisco Vagnaldo Fechine, Raquel Cavalcante de Vasconcelos, Maria Jânia Teixeira, Siulmara Cristina Galera, Zirlane Castelo Branco Coêlho |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Aging Endocrinology Diabetes and Metabolism Glutamine Renal function Administration Oral Kidney Blood Urea Nitrogen chemistry.chemical_compound Double-Blind Method Oral administration Internal medicine Medicine Humans Blood urea nitrogen Aged Aged 80 and over Creatinine Nutrition and Dietetics Cross-Over Studies biology business.industry Kidney metabolism Caseins Calcium caseinate Middle Aged Crossover study Endocrinology chemistry Liver Dietary Supplements biology.protein Female business Biomarkers Glomerular Filtration Rate |
| Zdroj: | Nutrition (Burbank, Los Angeles County, Calif.). 26(4) |
| ISSN: | 1873-1244 |
| Popis: | Objective To evaluate the safety of nutraceutical oral administration of l -glutamine ( l -Gln) in middle-aged and elderly individuals. Methods In this randomized, crossover, double-blind clinical study, 30 residents of a long-term–care institution, selected according to a modified SENIEUR protocol (Working Party of the EURAGE Concerted Action Programme on Ageing of the European Community), were studied. Fourteen subjects received orally 0.5 g · kg −1 · d −1 of l -Gln and 16 received calcium caseinate for 14 d, followed by a 5-d washout. Supplements were switched for the second 14-d trial. Laboratory tests for hepatic and renal functions and ammonemia were performed and the estimated glomerular filtration rate (eGFR) was calculated. Results Of the 30 subjects, 16 were men, mean age was 69 ± 8.8 y, average weight was 61.8 ± 14.2 kg, and mean serum albumin was 4.0 ± 0.3 g/dL. Neither adverse clinical effects nor clinically significant laboratory changes were noted during l -Gln supplementation. There was no difference in ammonemia between the groups. There were statistically but not clinically significant increases in plasma urea nitrogen and creatinine concentrations. There was no significant decrease in eGFR during calcium caseinate supplementation (−2.9%). The eGFR decreased significantly after l -Gln supplementation (−13.3%) but well below the 25% limit for biologic significance. Conclusion Increases in serum urea nitrogen and creatinine and decrease in eGFR are probably due to difficulties by older kidneys in metabolizing the supplemented protein sources. Although not clinically significant, those alterations impose a rigorous control on the evaluation parameters of renal function during oral l -Gln supplementation, with doses of 0.5 g · kg −1 · d −1 in middle-aged and elderly individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect